DOCSLIB.ORG

PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas Kristen S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas Kristen S Published OnlineFirst October 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0777 Oncogenes and Tumor Suppressors Molecular Cancer Research PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas Kristen S. Hill1, Evan R. Roberts1, Xue Wang1, Ellen Marin1, Taeeun D. Park1, Sorany Son1, Yuan Ren1, Bin Fang2, Sean Yoder3, Sungjune Kim4,5, Lixin Wan1, Amod A. Sarnaik6, John M. Koomen1,2, Jane L. Messina6,7, Jamie K. Teer8, Youngchul Kim8, Jie Wu9, Charles E. Chalfant10,11, and Minjung Kim1,6,10 Abstract Melanoma is one of the most highly mutated cancer types. noma tumorigenesis. Melanoma cells derived from this mouse To identify functional drivers of melanoma, we searched for model showed doxycycline-dependent tumor growth in nude cross-species conserved mutations utilizing a mouse melano- mice. Silencing PTPN11E76K expression by doxycycline with- ma model driven by loss of PTEN and CDKN2A, and identified drawal caused regression of established tumors by induction mutations in Kras, Erbb3, and Ptpn11. PTPN11 encodes of apoptosis and senescence, and suppression of proliferation. the SHP2 protein tyrosine phosphatase that activates the Moreover, the PTPN11 inhibitor (SHP099) also caused regres- Q61K RAS/RAF/MAPK pathway. Although PTPN11 is an oncogene sion of NRAS -mutant melanoma. Using a quantitative in leukemia, lung, and breast cancers, its roles in melanoma are tyrosine phosphoproteomics approach, we identified GSK3a/ not clear. In this study, we found that PTPN11 is frequently b as one of the key substrates that were differentially tyrosine- activated in human melanoma specimens and cell lines and is phosphorylated in these experiments modulating PTPN11. required for full RAS/RAF/MAPK signaling activation in BRAF This study demonstrates that PTPN11 plays oncogenic roles in wild-type (either NRAS mutant or wild-type) melanoma cells. melanoma and regulates RAS and GSK3b signaling pathways. PTPN11 played oncogenic roles in melanoma by driving anchorage-independent colony formation and tumor growth. Implications: This study identifies PTPN11 as an oncogenic In Pten- and Cdkn2a-null mice, tet-inducible and melanocyte- driver and a novel and actionable therapeutic target for BRAF specific PTPN11E76K expression significantly enhanced mela- wild-type melanoma. Introduction cross-species conserved genomic alterations, which led to the identification of cIAP and YAP1 as driver oncogenes in liver cancer Genetically engineered mouse models have been utilized to (1) and NEDD9 in melanoma (2). Whole-genome sequencing mine complex human genomic data to identify novel human analysis of a tumor developed in an acute promyelocytic leukemia cancer genes. Integration of high-resolution copy-number profiles (APL) mouse model uncovered recurrent somatic mutations in generated using mouse and human tumor genomes identified Jak1, pointing to the importance of the JAK/STAT pathway in pathogenesis of human APL (3). These studies have demonstrated that mice and humans sustain syntenic genetic events in the 1Department of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida. development of cancer, that mouse–human comparative onco- 2Department of Proteomics, Moffitt Cancer Center, Tampa, Florida. 3Molecular genomics can facilitate the discovery of new cancer genes that were 4 Genomics Core, Moffitt Cancer Center, Tampa, Florida. Department of not immediately obvious from the human cancer genome alone, fi 5 Immunology, Mof tt Cancer Center, Tampa, Florida. Department of Radiology, and that the mouse models may be utilized to gain insights into Moffitt Cancer Center, Tampa, Florida. 6Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida. 7Department of Pathology, Moffitt the function of these new cancer genes. Cancer Center, Tampa, Florida. 8Department of Biostatistics and Bioinformatics, Melanoma displays frequent activation of RAS/RAF/MAPK Moffitt Cancer Center, Tampa, Florida. 9Peggy and Charles Stephenson Cancer and PI3K/AKT signaling pathways, as well as inactivation of Center, University of Oklahoma Health Sciences Center, Oklahoma City, PTEN and CDKN2A (INK4A/ARF) tumor suppressors via genetic 10 Oklahoma. Department of Cell Biology, Microbiology, and Molecular Biology, and epigenetic alterations. The high frequency of activating muta- 11 University of South Florida, Tampa, Florida. Department of Research Service, tions in BRAF (40%–60%) and NRAS (15%–25%) support James A. Haley Veterans Hospital, Tampa, Florida. the importance of the RAS/RAF/MEK/ERK pathway in melanoma Note: Supplementary data for this article are available at Molecular Cancer (4, 5). Several recent genomic studies have identified mutations in Research Online (http://mcr.aacrjournals.org/). genes regulating the RAS pathway such as RasGAPs (NF1, RASA1, Corresponding Author: Minjung Kim, University of South Florida, 4202 East RASA2) and PTPN11 in melanoma (4, 6–10). These Ras regulators Fowler Ave., ISA2015, Tampa, FL 33620. Phone: 813-600-9441; Fax: 813-905- have the potential of being exploited as therapeutic targets. 9919; E-mail: [email protected] Protein-Tyrosine Phosphatase (PTP), Non-Receptor Type 11 doi: 10.1158/1541-7786.MCR-18-0777 (PTPN11, also known as SHP2) is ubiquitously expressed in Ó2018 American Association for Cancer Research. various tissues and cell types, and activates the Ras signaling www.aacrjournals.org 583 Downloaded from mcr.aacrjournals.org on September 28, 2021. © 2019 American Association for Cancer Research. Published OnlineFirst October 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0777 Hill et al. pathway as downstream of most, if not all, receptor tyrosine 5037, when tumors reached 200 mm3, mice were randomly kinases (RTK). PTPN11 contains two SH2 domains and a PTP enrolled onto vehicle control (1% carboxymethyl cellulose/ domain. PTPN11 is autoinhibited via a SH2–PTP domain inter- 0.5% Tween-80), MEK162 (25 mg/kg, p.o., b.i.d.), or SHP099 action and is activated by binding to tyrosine-phosphorylated (100 mg/kg, p.o., qd) treatment groups. All animals were RTKs, immune-inhibitory receptors, or docking proteins (such as maintained according to the guidelines of the Comparative Gab1/Gab2, IRS, FRS) and by point mutations that disrupt Medicine Department of the University of South Florida the SH2–PTP domain interaction. RTKs, such as EPHA2, (M4473 and R3312). phosphorylate Y542 and Y580 on PTPN11, which prolongs ERK activation by maintaining PTPN110s open conformation Whole-exome sequencing analysis of mouse melanomas with (11). Mutations in PTPN11 have been linked to Noonan and matched normal tissue LEOPARD syndromes and pathogenesis of multiple cancer types. Genomic DNA from 3 melanomas developed in IP mice with Oncogenic roles of PTPN11 in leukemia, lung, and breast matched normal tissue (kidney or tail) was subjected to whole- cancers have been established with PTPN11 regulating invasion, exome capture and paired-end sequencing on Illumina Hi-Seq metastasis, apoptosis, senescence, DNA damage, cell prolifera- 2000 sequencer by Beckman Coulter Genomics, Inc. Overall tion, cell-cycle progression, and drug resistance (12, 13). How- average coverage of 63.5X was achieved. Sequence reads obtained ever, PTPN11 has tumor-suppressive roles in liver cancer (14) and were aligned to the mm10 mouse reference sequence (C57BL/6J in bone/cartilage cancer (15), supporting PTPN110s cell context– strain) using the Burrows–Wheeler Alignment tool (18). Known dependent effects. SNPs of FVB/N mouse strain (strain background of the IP model) PTPN11 PTP activity regulates several molecules involved in from v.3 of the Mouse Genomes Project (19) and variants mapped Ras signaling (16). Specifically, PTPN11 negatively regulates outside of targeted region were removed. Utilizing Strelka (20), RasGAP recruitment by dephosphorylating RTKs (e.g., EGFR and somatic single-nucleotide variants (SNV) and small indels PDGFRb), leading to activation of Ras signaling. PTPN11 also were identified from the aligned sequencing reads of matched dephosphorylates PAG (phosphoprotein associated with glyco- tumor-normal samples. sphingolipid-enriched membrane microdomains) and paxillin, resulting in the release of CSK (C-terminal Src kinase) and Phosphoproteomic analysis subsequent activation of Src family kinases (SFK). A recent study Tumors were homogenized in denaturing buffer containing by Bunda and colleagues showed dephosphorylation and activa- 8 mol/L urea and clarified by centrifugation. Proteins were tion of Ras by PTPN11 (17). Additional targets of PTPN11 include reduced, alkylated, and digested overnight with trypsin Sprouty, signal regulatory protein-a, and protein zero-related. (Worthington). After buffer exchange, tyrosine-phosphorylated Although the list of PTPN11 substrates continues to grow, it is peptides were immunoprecipitated using anti-phosphotyrosine possible that PTPN11 dephosphorylates differential sets of sub- antibody beads (p-Tyr-100), followed by analysis on LC-MS/MS strates depending on the cell context in each cancer type. peptide sequencing (RSLC-QExactive Plus, Thermo), as previous- In this study, to identify functional driver mutations of mel- ly described (21). Label-free quantification by MaxQuant (22) anoma, we analyzed melanoma genomes from a mouse model produced 245 molecularly defined tyrosine phosphorylation sites driven by loss of CDKN2A (INK4A/ARF) and PTEN (IP model), with relative quantification for the levels of phosphorylation. commonly observed alterations in human melanoma patients, LIMMA analysis was then performed to identify
Load more

Recommended publications
  • Deciphering the Functions of Ets2, Pten and P53 in Stromal Fibroblasts in Multiple
    Deciphering the Functions of Ets2, Pten and p53 in Stromal Fibroblasts in Multiple Breast Cancer Models DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Julie Wallace Graduate Program in Molecular, Cellular and Developmental Biology The Ohio State University 2013 Dissertation Committee: Michael C. Ostrowski, PhD, Advisor Gustavo Leone, PhD Denis Guttridge, PhD Dawn Chandler, PhD Copyright by Julie Wallace 2013 Abstract Breast cancer is the second most common cancer in American women, and is also the second leading cause of cancer death in women. It is estimated that nearly a quarter of a million new cases of invasive breast cancer will be diagnosed in women in the United States this year, and approximately 40,000 of these women will die from breast cancer. Although death rates have been on the decline for the past decade, there is still much we need to learn about this disease to improve prevention, detection and treatment strategies. The majority of early studies have focused on the malignant tumor cells themselves, and much has been learned concerning mutations, amplifications and other genetic and epigenetic alterations of these cells. However more recent work has acknowledged the strong influence of tumor stroma on the initiation, progression and recurrence of cancer. Under normal conditions this stroma has been shown to have protective effects against tumorigenesis, however the transformation of tumor cells manipulates this surrounding environment to actually promote malignancy. Fibroblasts in particular make up a significant portion of this stroma, and have been shown to impact various aspects of tumor cell biology.
    [Show full text]
  • Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
    Leukemia (2010) 24, 756–764 & 2010 Macmillan Publishers Limited All rights reserved 0887-6924/10 $32.00 www.nature.com/leu ORIGINAL ARTICLE Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells A Pellagatti1, M Cazzola2, A Giagounidis3, J Perry1, L Malcovati2, MG Della Porta2,MJa¨dersten4, S Killick5, A Verma6, CJ Norbury7, E Hellstro¨m-Lindberg4, JS Wainscoat1 and J Boultwood1 1LRF Molecular Haematology Unit, NDCLS, John Radcliffe Hospital, Oxford, UK; 2Department of Hematology Oncology, University of Pavia Medical School, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 3Medizinische Klinik II, St Johannes Hospital, Duisburg, Germany; 4Division of Hematology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; 5Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK; 6Albert Einstein College of Medicine, Bronx, NY, USA and 7Sir William Dunn School of Pathology, University of Oxford, Oxford, UK To gain insight into the molecular pathogenesis of the the World Health Organization.6,7 Patients with refractory myelodysplastic syndromes (MDS), we performed global gene anemia (RA) with or without ringed sideroblasts, according to expression profiling and pathway analysis on the hemato- poietic stem cells (HSC) of 183 MDS patients as compared with the the French–American–British classification, were subdivided HSC of 17 healthy controls. The most significantly deregulated based on the presence or absence of multilineage dysplasia. In pathways in MDS include interferon signaling, thrombopoietin addition, patients with RA with excess blasts (RAEB) were signaling and the Wnt pathways. Among the most signifi- subdivided into two categories, RAEB1 and RAEB2, based on the cantly deregulated gene pathways in early MDS are immuno- percentage of bone marrow blasts.
    [Show full text]
  • The Proximal Signaling Network of the BCR-ABL1 Oncogene Shows a Modular Organization
    Oncogene (2010) 29, 5895–5910 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc ORIGINAL ARTICLE The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization B Titz, T Low, E Komisopoulou, SS Chen, L Rubbi and TG Graeber Crump Institute for Molecular Imaging, Institute for Molecular Medicine, Jonsson Comprehensive Cancer Center, California NanoSystems Institute, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA BCR-ABL1 is a fusion tyrosine kinase, which causes signaling effects of BCR-ABL1 toward leukemic multiple types of leukemia. We used an integrated transformation. proteomic approach that includes label-free quantitative Oncogene (2010) 29, 5895–5910; doi:10.1038/onc.2010.331; protein complex and phosphorylation profiling by mass published online 9 August 2010 spectrometry to systematically characterize the proximal signaling network of this oncogenic kinase. The proximal Keywords: adaptor protein; BCR-ABL1; phospho- BCR-ABL1 signaling network shows a modular and complex; quantitative mass spectrometry; signaling layered organization with an inner core of three leukemia network; systems biology transformation-relevant adaptor protein complexes (Grb2/Gab2/Shc1 complex, CrkI complex and Dok1/ Dok2 complex). We introduced an ‘interaction direction- ality’ analysis, which annotates static protein networks Introduction with information on the directionality of phosphorylation- dependent interactions. In this analysis, the observed BCR-ABL1 is a constitutively active oncogenic fusion network structure was consistent with a step-wise kinase that arises through a chromosomal translocation phosphorylation-dependent assembly of the Grb2/Gab2/ and causes multiple types of leukemia. It is found in Shc1 and the Dok1/Dok2 complexes on the BCR-ABL1 many cases (B25%) of adult acute lymphoblastic core.
    [Show full text]
  • To Study Mutant P53 Gain of Function, Various Tumor-Derived P53 Mutants
    Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression. A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science By Shama K Khokhar M.Sc., Bilaspur University, 2004 B.Sc., Bhopal University, 2002 2007 1 COPYRIGHT SHAMA K KHOKHAR 2007 2 WRIGHT STATE UNIVERSITY SCHOOL OF GRADUATE STUDIES Date of Defense: 12-03-07 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY SHAMA KHAN KHOKHAR ENTITLED Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science Madhavi P. Kadakia, Ph.D. Thesis Director Daniel Organisciak , Ph.D. Department Chair Committee on Final Examination Madhavi P. Kadakia, Ph.D. Steven J. Berberich, Ph.D. Michael Leffak, Ph.D. Joseph F. Thomas, Jr., Ph.D. Dean, School of Graduate Studies 3 Abstract Khokhar, Shama K. M.S., Department of Biochemistry and Molecular Biology, Wright State University, 2007 Differential effect of TAp63γ mutants on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression. p63, a member of the p53 gene family, known to play a role in development, has more recently also been implicated in cancer progression. Mice lacking p63 exhibit severe developmental defects such as limb truncations, abnormal skin, and absence of hair follicles, teeth, and mammary glands. Germline missense mutations of p63 have been shown to be responsible for several human developmental syndromes including SHFM, EEC and ADULT syndromes and are associated with anomalies in the development of organs of epithelial origin.
    [Show full text]
  • Biogenesis and Maintenance of Cytoplasmic Domains in Myelin of the Central Nervous System
    Biogenesis and Maintenance of Cytoplasmic Domains in Myelin of the Central Nervous System Dissertation for the award of the degree “Doctor rerum naturalium” of the Georg-August-Universität Göttingen within the doctoral program Molecular Biology of Cells of the Georg-August University School of Science (GAUSS) submitted by Caroline Julia Velte from Usingen, Germany Göttingen 2016 Members of the Thesis Committee: Prof. Dr. Mikael Simons, Reviewer Max Planck Institute of Experimental Medicine, Göttingen Prof. Dr. Andreas Janshoff, Reviewer Georg-August University, Göttingen Prof. Dr. Dirk Görlich Max Planck Institute of Biophysical Chemistry, Göttingen Date of the thesis defense: 27th of June 2016 Don't part with your illusions. When they are gone, you may still exist, but you have ceased to live. (Mark Twain) III Affidavit I hereby declare that my PhD thesis “Biogenesis and Maintenance of Cytoplasmic Domains in Myelin of the Central Nervous System” has been written independently with no other aids or sources than quoted. Furthermore, I confirm that this thesis has not been submitted as part of another examination process neither in identical nor in similar form. Caroline Julia Velte April 2016 Göttingen, Germany V Publications Nicolas Snaidero*, Caroline Velte*, Matti Myllykoski, Arne Raasakka, Alexander Ignatev, Hauke B. Werner, Michelle S. Erwig, Wiebke Moebius, Petri Kursula, Klaus-Armin Nave, and Mikael Simons Antagonistic Functions of MBP and CNP Establish Cytosolic Channels in CNS Myelin, Cell Reports 18 *equal contribution (January 2017) E. d’Este, D. Kamin, C. Velte, F. Göttfert, M. Simons, S.W. Hell Subcortical cytoskeleton periodicity throughout the nervous system, Scientific Reports 6 (March 2016) K.A.
    [Show full text]
  • 1 Validating Predicted Biological Effects of Alzheimer's Disease
    Journal of Alzheimer’s Disease ISSN: 1387-2877 IOS Press DOI: 10.3233/JAD-2010-091711 Validating Predicted Biological Effects of Alzheimer’s Disease Associated SNPs Using CSF Biomarker Levels John S.K. Kauwea,*, Carlos Cruchagab,*, Sarah Bertelsenb, Kevin Mayob, Wayne Latua, Petra Nowotnyb, Anthony L. Hinrichsb, Anne M. Faganc, David M. Holtzmanc, Alzheimer’s Disease Neuroimaging Initiative** and Alison M. Goateb aDepartment of Biology, Brigham Young University, Provo, UT, USA bDepartment of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA cDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA *Co-first authors with equal contributions. Running Title: Validating effects of AD risk variants Handling Associate Editor: Daniela Galimberti Accepted 16 April 2010 Correspondence to: Alison M. Goate, PhD, Samuel & Mae S. Ludwig Professor, Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, USA; Tel: +1 314-362-8691, Fax: +1 314-747-2983, Email: [email protected]. 1 **Some of the data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (http://www.loni.ucla.edu\ADNI). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. ADNI investigators include (complete listing available at http://www.loni.ucla.edu/ADNI/About/About_Investigators.shtml). 2 ABSTRACT Recent large-scale genetic studies of late-onset Alzheimer’s disease have identified risk variants in CALHM1, GAB2, and SORL1. The mechanisms by which these genes might modulate risk are not definitively known.
    [Show full text]
  • Domain Requires the Gab2 Pleckstrin Homology Negative Regulation Of
    Ligation of CD28 Stimulates the Formation of a Multimeric Signaling Complex Involving Grb-2-Associated Binder 2 (Gab2), Src Homology Phosphatase-2, and This information is current as Phosphatidylinositol 3-Kinase: Evidence That of October 1, 2021. Negative Regulation of CD28 Signaling Requires the Gab2 Pleckstrin Homology Domain Richard V. Parry, Gillian C. Whittaker, Martin Sims, Downloaded from Christine E. Edmead, Melanie J. Welham and Stephen G. Ward J Immunol 2006; 176:594-602; ; doi: 10.4049/jimmunol.176.1.594 http://www.jimmunol.org/content/176/1/594 http://www.jimmunol.org/ References This article cites 59 articles, 38 of which you can access for free at: http://www.jimmunol.org/content/176/1/594.full#ref-list-1 Why The JI? Submit online. by guest on October 1, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Ligation of CD28 Stimulates the Formation of a Multimeric Signaling Complex Involving Grb-2-Associated Binder 2 (Gab2), Src Homology Phosphatase-2, and Phosphatidylinositol 3-Kinase: Evidence That Negative Regulation of CD28 Signaling Requires the Gab2 Pleckstrin Homology Domain1 Richard V.
    [Show full text]
  • Time Resolved Quantitative Phosphoproteomics Reveals Distinct Patterns of SHP2
    bioRxiv preprint doi: https://doi.org/10.1101/598664; this version posted April 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Time resolved quantitative phosphoproteomics reveals distinct patterns of SHP2 dependence in EGFR signaling Vidyasiri Vemulapalli1,2, Lily Chylek3, Alison Erickson4, Jonathan LaRochelle1,2, Kartik Subramanian3, Morvarid Mohseni5, Matthew LaMarche5, Michael G. Acker5, Peter K. Sorger3, Steven P. Gygi4, and Stephen C. Blacklow1,2* 1Department of Cancer Biology, Dana-Farber Cancer Institute Boston, MA 02115, USA 2Department of Biological Chemistry & Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA 3Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA 4Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA 5Novartis Institutes for Biomedical Research, Cambridge, MA, 02139, USA *To whom correspondence should be addressed: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/598664; this version posted April 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract SHP2 is a protein tyrosine phosphatase that normally potentiates intracellular signaling by growth factors, antigen receptors, and some cytokines; it is frequently mutated in childhood leukemias and other cancers. Here, we examine the role of SHP2 in the responses of breast cancer cells to EGF by monitoring phosphoproteome dynamics when SHP2 is allosterically inhibited by the small molecule SHP099.
    [Show full text]
  • The Regulatory Roles of Phosphatases in Cancer
    Oncogene (2014) 33, 939–953 & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc REVIEW The regulatory roles of phosphatases in cancer J Stebbing1, LC Lit1, H Zhang, RS Darrington, O Melaiu, B Rudraraju and G Giamas The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases, including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumour suppressor, across tumour types lends credence to the development of phosphatidylinositol 3--kinase inhibitors alongside the use of phosphatase expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies. Oncogene (2014) 33, 939–953; doi:10.1038/onc.2013.80; published online 18 March 2013 Keywords: cancer; phosphatases; solid tumours GASTROINTESTINAL MALIGNANCIES abs in sera were significantly associated with poor survival in Oesophageal cancer advanced ESCC, suggesting that they may have a clinical utility in Loss of PTEN (phosphatase and tensin homologue deleted on ESCC screening and diagnosis.5 chromosome 10) expression in oesophageal cancer is frequent, Cao et al.6 investigated the role of protein tyrosine phosphatase, among other gene alterations characterizing this disease. Zhou non-receptor type 12 (PTPN12) in ESCC and showed that PTPN12 et al.1 found that overexpression of PTEN suppresses growth and protein expression is higher in normal para-cancerous tissues than induces apoptosis in oesophageal cancer cell lines, through in 20 ESCC tissues.
    [Show full text]
  • PTPN11 Is the First Identified Proto-Oncogene That Encodes a Tyrosine Phosphatase
    From www.bloodjournal.org by guest on July 4, 2016. For personal use only. Review article PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase Rebecca J. Chan1 and Gen-Sheng Feng2,3 1Department of Pediatrics, the Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis; 2Programs in Signal Transduction and Stem Cells & Regeneration, Burnham Institute for Medical Research, La Jolla, CA; 3Institute for Biomedical Research, Xiamen University, Xiamen, China Elucidation of the molecular mechanisms 2 Src-homology 2 (SH2) domains (Shp2). vation of the Ras-Erk pathway. This underlying carcinogenesis has benefited This tyrosine phosphatase was previ- progress represents another milestone in tremendously from the identification and ously shown to play an essential role in the leukemia/cancer research field and characterization of oncogenes and tumor normal hematopoiesis. More recently, so- provides a fresh view on the molecular suppressor genes. One new advance in matic missense PTPN11 gain-of-function mechanisms underlying cell transforma- this field is the identification of PTPN11 mutations have been detected in leuke- tion. (Blood. 2007;109:862-867) as the first proto-oncogene that encodes mias and rarely in solid tumors, and have a cytoplasmic tyrosine phosphatase with been found to induce aberrant hyperacti- © 2007 by The American Society of Hematology Introduction Leukemia and other types of cancer continue to be a leading cause tumor suppressor activity when overexpressed in vitro, and Ptprj of death in the United States, and biomedical scientists sorely note maps to the mouse colon cancer susceptibility locus,3 implicating that victories against cancer remain unacceptably rare.
    [Show full text]
  • Structure and Function of Gab2 and Its Role in Cancer (Review)
    MOLECULAR MEDICINE REPORTS 12: 4007-4014, 2015 Structure and function of Gab2 and its role in cancer (Review) CHEN-BO DING1, WEI-NA YU1, JI-HONG FENG2 and JUN-MIN LUO1 1Department of Immunology and Immunology Innovation Base for Postgraduate Education in Guizhou Province, Zunyi Medical University; 2Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563099, P.R. China Received September 11, 2014; Accepted May 19, 2015 DOI: 10.3892/mmr.2015.3951 Abstract. The docking proteins of the Grb-associated binder 1. Introduction (Gab) family transduce cellular signals between receptors and intracellular downstream effectors, and provide a platform Gab2 belongs to the Grb-associated binder (Gab) family of for protein-protein interactions. Gab2, a key member of the docking proteins, which also includes mammalian Gab1, Gab family of proteins, is involved in the amplification and Gab3 and Gab4, Drosophila daughter of sevenless, and integration of signal transduction, evoked by a variety of Caenorhabditis elegans suppressor of Clr-1 (1). Gab2 is extracellular stimuli, including growth factors, cytokines reported to contain a pleckstrin homology (PH) domain at and antigen receptors. Gab2 protein lacks intrinsic catalytic the N-terminus, several proline-rich motifs (PXXP) and activity; however, when phosphorylated by protein-tyrosine multiple tyrosine residues, which couple with SH2-containing kinases (PTKs), Gab2 recruits several Src homology-2 (SH2) molecules in a phosphorylation-dependent manner (1,2). The domain-containing proteins, including the SH2-containing Gab2 PH domain preferentially combines phosphatidylino- protein tyrosine phosphatase 2 (SHP2), the p85 subunit of sitol 3,4,5-P3 (PIP3) (3). In Gab2, two of the proline-rich motifs phosphoinositide-3 kinase (PI3K), phospholipase C-γ (PLCγ)1, are Grb2-Src homology (SH3) domain binding sites (4), which Crk, and GC-GAP.
    [Show full text]
  • Hypomethylation-Linked Activation of PLCE1 Impedes Autophagy and Promotes Tumorigenesis Through MDM2-Mediated Ubiquitination and Destabilization of P53
    Author Manuscript Published OnlineFirst on February 17, 2020; DOI: 10.1158/0008-5472.CAN-19-1912 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Hypomethylation-linked activation of PLCE1 impedes autophagy and promotes tumorigenesis through MDM2-mediated ubiquitination and destabilization of p53 Yunzhao Chen1,3*, Huahua Xin1*, Hao Peng1*, Qi Shi1, Menglu Li1, Jie Yu3, Yanxia Tian1, Xueping Han1, Xi Chen1, Yi Zheng4, Jun Li5, Zhihao Yang1, Lan Yang1, Jianming Hu1, Xuan Huang2, Zheng Liu2, Xiaoxi Huang2, Hong Zhou6, Xiaobin Cui1**, Feng Li1,2** 1 Department of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi 832002, China; 2 Department of Pathology and Medical Research Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China; 3 The people's hospital of Suzhou National Hi-Tech District, Suzhou 215010, China; 4 Department of Gastroenterology, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi 832002, China; 5 Department of Ultrasound, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi 832002, China; 6 Bone Research Program, ANZAC Research Institute, The University of Sydney, Sydney, Australia. Running title: PLCE1 impedes autophagy via MDM2-p53 axis in ESCC *These authors contributed equally to this work. Corresponding authors: **Xiaobin Cui, Department of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi 832002, China. Phone: 86.0377.2850955; E-mail: [email protected]; **Feng Li, Department of Pathology and Medical Research Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
    [Show full text]